Date: 2017-03-06
Type of information: Nomination
Compound:
Company: Amag Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 6, 2017, Amag Pharmaceuticals announced changes to its executive and commercial leadership teams, including that Frank Thomas, president and chief operating officer, intends to transition out of the organization on April 30, 2017. Following this transition, Ted Myles, chief financial officer, and Joseph Vittiglio, general counsel, along with Amag’s business development function, will report directly to William Heiden, chief executive officer of Amag. Mr. Vittiglio joined Amag as chief counsel in August 2015, and Mr. Myles joined the company as chief financial officer in April 2016.
- Amag also announced key commercial leadership moves to drive future growth in maternal and women’s health, following the company’s recently announced licensing transactions for Intrarosa® (prasterone) and bremelanotide. Paul Williams, who currently leads the company’s maternal health organization, has been appointed to lead Amag’s newly created women’s health business. Mr. Williams, who joined Amag in 2014, will be responsible for the launch and commercialization of Intrarosa®, as well as the potential launch of bremalanotide in early 2019.
- Mary Trout, who joined Amag in 2015 as part of the CBR acquisition and successfully led the integrated maternal health field sales force to achieve record sales for Makena over the past two years, has been promoted to senior vice president of sales and marketing, maternal health. In her new role, Ms. Trout will lead Amag’s maternal health commercial functions. Both Mr. Williams and Ms. Trout will report to Nik Grund, Amag’s chief commercial officer.
Financial terms:
Latest news:
Is general: Yes
